Neurology News

Biotech firm SynaptixBio has entered into a licensing agreement with the Children’s Hospital of Philadelphia, also known as CHOP, to develop a treatment for TUBB4a leukodystrophy, a rare and fatal neurodegenerative disorder.

Erenumab was not effective in reducing pain intensity in patients with trigeminal neuralgia, researchers reported in Lancet Neurology.

Those who survive 30 days of SARS-CoV-2 infection have an increased risk for neurological disorders after 1 year compared with those who were not infected, according to a report in Nature Medicine.

A patient’s age, severity of symptoms, number of previous concussions and family history of psychiatric disorders were associated with a need for additional care before student athletes with concussion could return to play.

In this edition, preventive therapies should be offered for migraines; targeting neuropathic symptoms for poststroke pain; PDE5 inhibitors not associated with lower AD, dementia risk and more.

Amydis Inc. announced that patient enrollment in underway for a phase 1/2a trial to evaluate AMDXP-2011P, a retinal imaging agent that targets protein biomarkers in patients with Parkinson’s disease and ALS.

A Tulane University neurosurgeon is among the first to perform a procedure with Minnetronix Medical’s MindsEye expandable port, a minimally invasive device for surgical treatment of stroke, cancer and other neurological conditions.

Premenopausal and perimenopausal women with a history of migraines were more likely to experience poor sleep vs. those who did not have a history of migraines, according to a cross-sectional study presented at the NAMS Annual Meeting.

Supernus Pharmaceuticals Inc. announced that the FDA has issued a complete response letter for its new drug application of SPN-830, requesting more information.

Antidepressant use in pregnancy was not associated with neurodevelopmental disorders in offspring, according to a cohort study published in JAMA Internal Medicine.